http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2565403-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba4d5480847b44d1d3b9833dfed7115c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-608 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-436 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-10 |
| filingDate | 2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2559fdf8050bfea83ed5a4337f7f823 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d8a6fda4a49e4052187c37d96962ee3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_254976e016736ba7b97068b6a9190580 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de5552e3dbe27ea3c9d53a39f0c5384a |
| publicationDate | 2015-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2565403-C2 |
| titleOfInvention | Local delivery of combination of adenosine a2a receptor agonists/phosphodiesterase inhibitor in vessels to relieve myocardial involvement severity |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine. What is described is a medical device applicable for local delivery of a selective adenosine receptor agonist combined with other drugs; it is used for relieving a myocardial involvement following myocardial infarction. As soon as possible after the myocardial infarction, a stent or any other applicable device comprising or able to deliver the selective adenosine receptor agonist is placed in a blood vessel, wherein an occlusion caused the infarction occurred. After being placed, the stent or any other intraluminal device is stretched to eliminate the occlusion and to recover the blood flow in a certain cardiac region, segment or tissue. Over a specified period of time, the selective adenosine receptor agonist either separately or in a combination with the other drugs elutes from the stent or other device into an underlying coronary blood flow to the cardiac tissue involved into hypoxia for a period of time sufficient enough to reduce the myocardial involvement. n EFFECT: stents reduces the rate of restenosis considerably. n 13 cl, 19 dwg |
| priorityDate | 2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 345.